Dark

Check out our Level2View

OCUP
Ocuphire Pharma, Inc. Common Stock
stock NASDAQ

Inactive

Oct 23, 2024

1.17USD-12.030%(-0.16)676,715

Pre-market

0.00USD-100.000%(-1.33)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 31, 2022

06:03AM EST Ocuphire Presenting New Data And Updates On APX3330 And Nyxol Clinical Programs At Virtual Investor R&D Day Benzinga

06:00AM EST New data support Phase 3 development of Nyxol alone as a durable single eye drop for the potential treatment of Presbyopia GlobeNewswire Inc

Jan 25, 2022

07:00AM EST Update on Late-Stage Clinical Trials in the APX3330 and Nyxol Programs as well as Commercial Insights for Nyxol for RM and Presbyopia by Six Leading KOLs GlobeNewswire Inc

Jan 5, 2022

07:03AM EST Ocuphire Provides Corporate Update: Announces Enrollment Completion Of Phase 3 Nyxol Trial, Enrollment Initiation Of Nyxol Pediatric Trial And Investor R&D Day In January Benzinga

07:00AM EST Ocuphire Provides Corporate Update: Announcing Enrollment GlobeNewswire Inc

Dec 8, 2021

08:00AM EST Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that it has appointed six new key opinion leaders (KOLs) across retina, refractive surgery, and optometry to its Medical Advisory Board (MAB). GlobeNewswire Inc

Nov 24, 2021

03:04PM EST Mid-Afternoon Market Update: Dow Falls 75 Points; Biofrontera Shares Spike Higher Benzinga

12:32PM EST Mid-Day Market Update: Gap Drops Following Downbeat Q3 Results; Ocuphire Pharma Shares Jump Benzinga

10:06AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 24, 2021 Benzinga

09:56AM EST Ocuphire Pharma Option Alert: Dec 17 $7.5 Calls Sweep (6) near the Ask: 1000 @ $0.3 vs 0 OI; Ref=$4.9797 Benzinga

09:18AM EST Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Nov. 24, 2021: KTTA, APVO, TSLA, BFRI, OCUP Benzinga

06:09AM EST HC Wainwright & Co. Initiates Coverage On Ocuphire Pharma with Buy Rating, Announces Price Target of $26 Benzinga

Nov 23, 2021

09:04AM EST Ocuphire Announces Enrollment Of First Patients In Second Phase 3 Pivotal Trial (MIRA-3) For Nyxol In Reversal of Mydriasis Benzinga

09:00AM EST RM Indication Allows for Rapid Recruitment with Top-line Results Expected in Early 2022 GlobeNewswire Inc

Nov 12, 2021

07:47AM EST The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares Benzinga

07:16AM EST Ocuphire Pharma Q3 EPS $(0.25) Up From $(0.33) YoY Benzinga

07:00AM EST On Track to Initiate Additional Phase 3 FDA Registration Trials for Nyxol Eye Drops in Reversal of Mydriasis (RM) in 4Q21 and Presbyopia in 1H22 GlobeNewswire Inc

Nov 8, 2021

08:29AM EST The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Benzinga

Nov 1, 2021

09:32AM EDT Ocuphire Invited To Present Clinical Data On Nyxol And APX3330 At American Academy Of Ophthalmology 2021 Annual Meeting And Eyecelerator/AAO Meeting Benzinga

09:31AM EDT FDA Approves First Pharmaceutical Therapy to Treat Presbyopia; Nyxol on Track to Start Phase 3 Presbyopia Trials in First Half of 2022 GlobeNewswire Inc

Oct 7, 2021

07:04AM EDT Ocuphire Announces Publications Featuring The Ref-1 Protein, A Transcription Factor Regulator, As A Novel Therapeutic Target For The Treatment Of Neovascular Retinal Diseases Benzinga

07:00AM EDT New Review Publications Underscore the Role of the APE1/Ref-1 Protein in Multiple Pro-angiogenic Pathways Associated with Neovascular Eye Disease Including Diabetic Retinal Diseases and Age-Related Macular Degeneration GlobeNewswire Inc

Oct 1, 2021

08:51AM EDT Ocuphire Pharma To Present Data On Phase 2b Trial For APX3330 For Retina At Ophthalmology Innovation Summit Retina@ASRS Innovation Company Showcase Oct. 7 At 10:16 a.m. EDT, Diabetic Symposium Oct. 9 9:51 a.m. EDT Benzinga

08:50AM EDT Ocuphires Clinical Phase 2b Oral Drug Candidate GlobeNewswire Inc

Sep 29, 2021

10:01AM EDT From BZ's Small Cap Healthcare Conference: Ocuphire Pharma Founder & CEO, Mina Sooch Says Co Will Create $700 Million In Revenues Around 2023 Benzinga

09:52AM EDT From BZ's Small Cap Healthcare Conference: Ocuphire Pharma Founder & CEO, Mina Sooch Begin Presenting Benzinga

Sep 27, 2021

07:00AM EDT Ocuphire Pharma Presenting at Three UpcomingHealthcare GlobeNewswire Inc

Sep 3, 2021

05:00PM EDT Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq GlobeNewswire Inc

Sep 2, 2021

07:00AM EDT Ocuphire Pharma Presenting at Four Conferences in September GlobeNewswire Inc

Aug 12, 2021

07:32AM EDT Ocuphire Pharma Q2 EPS $(0.52) Down From $(0.43) YoY Benzinga

07:00AM EDT Continued Momentum in Nyxol Programs with Announcement of Positive Top-Line Results from VEGA-1 Phase 2 Trial in Presbyopia GlobeNewswire Inc

Aug 6, 2021

07:30AM EDT Canaccord Genuity 41st Annual Growth Conference being held virtually on August 10-12, 2021 GlobeNewswire Inc

Jul 22, 2021

08:01AM EDT Ocuphire Highlights Publication In The Journal Of Cellular Signaling Featuring Its Oral Ref-1 Inhibitor APX3330 In Phase 2 Trial For The Treatment Of Retinal Disease Benzinga

08:00AM EDT Highlights Favorable Safety Profile of the Oral New Chemical Entity APX3330 and Its Novel Anti-Angiogenic and Anti-Inflammatory Mechanism of Action Properties Relevant to a Broad Range of Retinal Diseases GlobeNewswire Inc

Jul 13, 2021

09:06AM EDT Ocuphire Says Selected To Present At Multiple Ophthalmic Conferences In July Benzinga

09:01AM EDT Positive Results from Phase 2 Presbyopia (VEGA-1) and Phase 3 Reversal of Mydriasis (MIRA-2) Studies to be Presented at 2021 ASCRS Annual Meeting in Las Vegas GlobeNewswire Inc

Jul 9, 2021

05:02PM EDT Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq GlobeNewswire Inc

Jun 30, 2021

08:00AM EDT Ocuphire Pharma Stock Surges After Nyxol Combo Treatment Meets Study Endpoints In Presbyopic Patients Benzinga

07:16AM EDT Ocuphire Announces VEGA-1 Phase 2 Trial In Presbyopia Meets Primary And Secondary Endpoints Benzinga

07:15AM EDT Met primary endpoint with statistical significance at 1 hour with 61% of subjects treated with Nyxol plus low-dose pilocarpine (LDP) gaining 15 letters (3 lines) in near vision GlobeNewswire Inc

Jun 17, 2021

01:55PM EDT Processa Pharmaceuticals In-Licenses Ocuphire's Anticancer Agent Benzinga

09:20AM EDT Processa Pharmaceuticals Says Enters Into Licensing Agreement With Ocuphire Pharma For Development Of RX-3117 Benzinga

09:15AM EDT PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH GlobeNewswire Inc

Jun 11, 2021

07:33AM EDT Ocuphire Announces Addition To Russell Microcap Index Benzinga

Jun 8, 2021

04:10PM EDT Ocuphire Announces Closing of $15 Million Registered Direct GlobeNewswire Inc

08:13AM EDT Ocuphire Names Jay Pepose To Board RTTNews

08:00AM EDT Ocuphire Announces Appointment of Jay S. Pepose, M.D., Ph.D. to GlobeNewswire Inc

Jun 4, 2021

09:07AM EDT Ocuphire Announces $15M Registered Direct Offering Of 3.076M Shares Priced At-the-Market Benzinga

09:04AM EDT Ocuphire Announces $15 Million Registered Direct Offering Priced GlobeNewswire Inc

May 20, 2021

07:30AM EDT Highlights of Recent Positive Data from Nyxols Phase 3 Registration Trial GlobeNewswire Inc

May 18, 2021

07:40AM EDT Ocuphire: USPTO Issues Two Patents Covering Late-Stage Drug Candidate Nyxol, Including For The Treatment Of Presbyopia RTTNews

07:35AM EDT Ocuphire Granted Two New US Patents Covering Nyxol, Including For Treatment Of Presbyopia Benzinga

07:30AM EDT Newly Issued Claims Extend Patent Protection to Year 2039 for Nyxol Combination Therapy for Presbyopia GlobeNewswire Inc

May 12, 2021

07:35AM EDT Ocuphire Pharma Completes Enrollment In VEGA-1 Phase 2 Clinical Trial Of Nyxol With Low-Dose Pilocarpine For Presbyopia RTTNews

07:32AM EDT Ocuphire Completes Enrollment In VEGA-1 Phase 2 Clinical Trial Investigating Nyxol In Combination With Low-Dose Pilocarpine For Treatment Of Presbyopia Benzinga

07:30AM EDT Ocuphire Completes EnrollmentinVEGA-1 GlobeNewswire Inc

May 7, 2021

08:06AM EDT Ocuphire Pharma Q1 EPS $(0.47) Up From $(0.93) YoY Benzinga

08:00AM EDT Reported Positive Data in First Pivotal Phase 3 Trial for Nyxol Eye Drops with Plans to Advance Towards NDA Submission and Commercialization in Reversal of Mydriasis Indication GlobeNewswire Inc

May 4, 2021

07:42AM EDT Ocuphire Pharma Granted U.S. Patent Titled 'Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders' Benzinga

Apr 22, 2021

08:10AM EDT Ocuphire Pharma Says Co's APX3330 For Retinal Diseases To Be Presented At 2021 Association For Research In Vision And Ophthalmology Virtual Annual Meeting Benzinga

08:00AM EDT Oral Administration of APX3330 Reduced Neovascularization in a Pre-Clinical Mouse Model of Laser-Induced Choroidal Neovascularization GlobeNewswire Inc

Apr 19, 2021

10:18AM EDT Stocks That Hit 52-Week Lows On Monday Benzinga

Apr 8, 2021

10:43AM EDT Ocuphire Pharma Starts Mid-Stage APX3330 Study In Diabetic Retinopathy Patients Benzinga

08:34AM EDT Ocuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 In Diabetic Retinopathy Benzinga

08:31AM EDT APX3330has the Potential to be a Novel Oral Treatment Option with Dual Mechanism ofAnti-VEGF and Anti-Inflammatory for Diabetic Retinopathy GlobeNewswire Inc

Apr 5, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2021 Benzinga

07:16AM EDT Alliance Global Partners Initiates Coverage On Ocuphire Pharma with Buy Rating, Announces Price Target of $25 Benzinga

Apr 1, 2021

05:11PM EDT Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq GlobeNewswire Inc

Mar 29, 2021

01:12PM EDT Ocuphire Pharma shares were trading higher after JonasTrading initiated coverage on the stock with a Buy rating and announced a price target of $20 per share. Benzinga

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2021 Benzinga

07:32AM EDT JonesTrading Initiates Coverage On Ocuphire Pharma with Buy Rating, Announces Price Target of $20 Benzinga

Mar 26, 2021

04:13PM EDT Apexian Pharmaceuticals, Inc. Discloses 7.136% Passive Stake In Ocuphire Pharma Benzinga

Mar 15, 2021

12:55PM EDT Cantor Fitzgerald Maintains Overweight on Ocuphire Pharma, Raises Price Target to $20 Benzinga

11:11AM EDT Ocuphire Pharma shares were trading higher after the company announced that its MIRA-2 Phase 3 registration trial for the reversal of Mydriasis Met its primary endpoint. Benzinga

06:38AM EDT Ocuphire Pharma Stock Is Trading Higher After Nyxol Aces Late-Stage Study Benzinga

06:05AM EDT Ocuphire Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint Benzinga

06:00AM EDT Nyxol Meets Its Primary and Multiple Secondary Endpoints Including Statistically Significant Efficacy Returning Subjects More Rapidly to Normal Pupil Size Across a Breadth of Dilating Agents and Iris Colors GlobeNewswire Inc

Mar 10, 2021

04:35PM EST Ocuphire Pharma Reports FY20 EPS $(5.28) Down From $(2.17) YoY Benzinga

04:30PM EST Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced financial results for the full year 2020 and provided a corporate update. GlobeNewswire Inc

Mar 5, 2021

08:49AM EST Ocuphire Highlights Publication Of MIRA-1 Phase 2b Results In Optometry And Visual Science Demonstrating Reduction Of Pharmacologically Induced Mydriasis By Nyxol Benzinga

08:44AM EST Efficacy Across Mydriatic Agents in Reversing Pharmacologically Induced Mydriasis Informed Phase 3 Registration MIRA-2 Study Design GlobeNewswire Inc

Mar 4, 2021

08:27AM EST HC Wainwright Life Sciences Conference beginning at 7:00 am ET on March 9thOppenheimer Healthcare Conference at 9:20 am ET on March 18th GlobeNewswire Inc

Feb 18, 2021

08:54AM EST Ocuphire Initiates Enrollment In VEGA-1 Phase 2 Trial Investigating Nyxol In Presbyopia Benzinga

08:54AM EST Nyxol and Low-Dose (0.4%) Pilocarpine Combination to Target Improvement in Near Vision in a Presbyopic Population GlobeNewswire Inc

Feb 11, 2021

09:13AM EST Ocuphire to Participate in the 2021 BIO CEO & Investor Conference GlobeNewswire Inc

Feb 10, 2021

11:17AM EST Canaccord Genuity Initiates Coverage On Ocuphire Pharma with Buy Rating, Announces Price Target of $22 Benzinga

Feb 4, 2021

07:30AM EST Ocuphire Files For Mixed Shelf Offering of Up To $125M Benzinga

Jan 20, 2021

07:00AM EST Ocuphire Announces Publication of ORION-1 Phase 2 Results for Nyxol in Clinical Ophthalmology and Presentation at the January OIS Presbyopia Innovation Showcase Benzinga

07:00AM EST Durability of Nyxols Pupil Constricting Effects Using an Evening Dosing Regimen Informs Dosing Strategy for Phase 2 Trial in Presbyopia and Phase 3 Trial in NVD GlobeNewswire Inc

Jan 6, 2021

07:10AM EST Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol for Reversal of Mydriasis Benzinga

07:00AM EST Nyxol has Potential to be a New Treatment Option for Reversal of Pharmacologically-Induced Pupil Dilation GlobeNewswire Inc

Jan 5, 2021

07:15AM EST Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol In Night Vision Disturbances Benzinga

07:00AM EST Nyxol is in Late Stage Clinical Development for A New Ophthalmic Indication GlobeNewswire Inc

Dec 30, 2020

08:30AM EST Ocuphire to Present at the LifeSci Partners 10th Annual Healthcare GlobeNewswire Inc

Dec 8, 2020

07:00AM EST Ocuphire to be Featured in Cantor Fitzgerald Fireside Chat with GlobeNewswire Inc

Nov 20, 2020

11:48AM EST Benzinga's Top Upgrades, Downgrades For November 20, 2020 Benzinga

06:40AM EST Cantor Fitzgerald Initiates Coverage On Ocuphire Pharma with Overweight Rating, Announces Price Target of $15 Benzinga

Nov 19, 2020

07:01AM EST Ocuphire Pharma Announces First Patient Enrolled in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol for Reversal of Mydriasis Benzinga

07:00AM EST Begins Enrollment in the First of Four Upcoming Late-Stage Trials in the U.S. GlobeNewswire Inc

Nov 16, 2020

06:09AM EST Ocuphire Pharma Announces Global Patents for Nyxol, APX3330 Program Receives $1.7M Grand From the National Institute of Health Benzinga

06:00AM EST AllowedJapanese Patent Application for Daily Ophthalmic Use of Nyxol to Improve Visual Performance GlobeNewswire Inc

Nov 12, 2020

06:00AM EST Ocuphire Pharma Announces Two Publications Supporting the APX3330 GlobeNewswire Inc

Nov 10, 2020

10:09AM EST Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced that will participate in the H.C. Wainwright 6th Annual Israel Conference on November 12th, 2020. GlobeNewswire Inc

08:40AM EST The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga

Nov 6, 2020

06:00AM EST Industry Veteran Susan Benton Joins the Ocuphire Pharma Board of GlobeNewswire Inc

Share